Cambridge, Mass. — Cellarity, a Flagship Pioneering-founded biotechnology company focused on transforming drug discovery through AI and single-cell analysis, has appointed industry veteran Ted Myles as its new Chief Executive Officer. Myles will also join Flagship Pioneering as a CEO-Partner, the organizations announced Monday.
The appointment comes at a pivotal time for Cellarity as the company prepares to enter clinical trials for its lead program, CLY-124, a potential first-in-class treatment for sickle cell disease. CLY-124, developed using Cellarity’s proprietary AI/ML-enabled platform, works by inducing fetal hemoglobin through a novel mechanism identified via single-cell transcriptomic analysis. The company expects the program to enter the clinic by mid-2025.
Myles brings more than two decades of biopharma leadership experience, having previously served as CFO and COO at Scholar Rock, where he helped guide the company through a successful Phase 3 registrational study and raised over $1 billion in capital. He has also held executive roles at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx—each of which were acquired under his financial and operational leadership.
“Cellarity is approaching a critical milestone with its first clinical study on the horizon, and Ted’s leadership will be instrumental in maximizing the impact of the company’s scientific platform,” said Stephen Berenson, Chairman of Cellarity’s Board and Managing Partner Emeritus at Flagship Pioneering. “We are excited to welcome him aboard at this important juncture.”
Myles expressed enthusiasm for the opportunity, noting the company’s unique position at the intersection of data science, biology, and chemistry. “Cellarity is a powerhouse of AI-powered biotechnology,” he said. “Its platform is producing highly novel programs in important disease areas, and I’m excited to lead this exceptional team as we transition into clinical development and expand into new indications.”
Founded by Flagship Pioneering, Cellarity uses single-cell data and machine learning to map how diseases alter cellular behavior and identify new therapeutic targets. The company’s platform aims to generate first-in-class medicines by targeting cellular dysfunctions rather than single genes or proteins—an approach that may offer higher clinical success rates for complex diseases.
Noubar Afeyan, co-founder of Cellarity and CEO of Flagship Pioneering, praised the appointment as a catalyst for the company’s next phase. “Ted is the right leader to take the helm,” Afeyan said. “His executive acumen and strategic vision will help Cellarity scale its platform and deepen its impact across the Flagship ecosystem.”
As the company moves into clinical development, Cellarity is expected to continue advancing its pipeline of AI-driven small molecule therapies aimed at a broad range of diseases with unmet needs.
